The RNA-binding protein SART3 promotes miR-34a biogenesis and G₁ cell cycle arrest in lung cancer cells

MicroRNAs (miRNAs or miRs) are small, noncoding RNAs that are implicated in the regulation of most biological processes. Global miRNA biogenesis is altered in many cancers, and RNA-binding proteins play a role in miRNA biogenesis, presenting a promising avenue for targeting miRNA dysregulation in diseases. miR-34a exhibits tumor-suppressive activities by targeting cell cycle regulators CDK4/6 and anti-apoptotic factor BCL-2, among other regulatory pathways such as Wnt, TGF-ß, and Notch signaling. Many cancers exhibit down-regulation or loss of miR-34a, and synthetic miR-34a supplementation has been shown to inhibit tumor growth in vivo. However, the post-transcriptional mechanisms that cause miR-34a loss in cancer are not entirely understood. Here, using a proteomics-mediated approach in non-small-cell lung cancer (NSCLC) cells, we identified squamous cell carcinoma antigen recognized by T-cells 3 (SART3) as a putative pre-miR-34a–binding protein. SART3 is a spliceosome recycling factor and nuclear RNA-binding protein with no previously reported role in miRNA regulation. We found that SART3 binds pre-miR-34a with higher specificity than pre-let-7d (used as a negative control) and elucidated a new function as a spliceosome recycling factor and nuclear RNA-binding protein. In vitro binding experiments revealed that the RNA-recognition motifs within the SART3 sequence are responsible for selective pre-miR-34a binding. Our results provide evidence for a significant role of SART3 in miR-34a biogenesis and cell cycle progression in NSCLC cells.

RNA-binding proteins (RBPs)² are proteins containing one or more RNA-binding domains and have been widely implicated in post-transcriptional regulation of gene expression (1–3). RBPs serve as mediators of RNA transcription (4), modification (5, 6), splicing (6, 7), transport (8, 9), and turnover (10). For many years, RBPs were almost exclusively studied with respect to mRNA (11, 12); however, more recently, an improved understanding of RNA biology and next-generation sequencing technologies have led to the discovery of new roles for RBPs as regulators of noncoding RNAs such as miRNAs (11, 13–17).

miRNAs are a class of small noncoding RNA that act as post-transcriptional regulators of gene expression. Briefly, miRNAs are transcribed as several-kb primary transcripts (pri-miR) by RNA polymerase II (18, 19). This pri-miR is processed by the nuclear Microprocessor complex, composed of Drosha and DiGeorge syndrome critical region 8 (DGCR8), resulting in a 60–80-nucleotide pre-miR hairpin (20–23). Following nuclear export by Exportin-5, the pre-miR is processed by Dicer to yield a mature miRNA duplex (24–27). The guide strand of the duplex is loaded onto an Argonaute (AGO) protein to form the RNA-induced silencing complex (RISC), whereas the passenger strand is degraded (28–30). RISC then facilitates silencing of miRNA target gene transcripts (31–33).

The canonical miRNA biogenesis pathway can be disrupted in cancers, and miRs with tumor-suppressive functions are often down-regulated in these diseased states (34–36). RBPs have recently garnered increased attention as modulators of miRNA processing and potential contributors to loss of miRNA activity (13–17). A prominent example is the let-7–Lin28 miRNA-protein interaction, which has been shown to promote several forms of human cancer (34, 37–40). The let-7 family of miRNA has been widely implicated in tumor suppression by targeting oncogenes such as RAS and Myc (34, 41). Lin28 protein binds the hairpin loop of pri- or pre-let-7 to inhibit processing by Drosha or Dicer, respectively, leading to let-7 degradation (42–44).

miR-34a is one of the most extensively characterized miRs and has been shown to mediate tumor suppression by targeting the Notch (45, 46), TGF-ß (47), and Wnt signaling pathways (48), as well as influencing the cell cycle (49, 50), senescence (51, 52), and apoptosis. Like let-7, as a tumor suppressor, miR-34a is lost or down-regulated in multiple cancers (53–55). Transcriptional regulation of miR-34a has been widely studied; miR-34a is transcriptionally induced by the p53 tumor suppressor (50, 56,

This is an Open Access article under the CC BY license.
Results

**SART3 is a putative pre-miR-34a–binding protein**

To identify proteins in the miR-34a interactome, we first established a method for miR-binding protein discovery in mammalian cells (Fig. 1A). In brief, a 5’ biotinylated pre-miR is used as bait and incubated with cell lysate, enabling subsequent pulldown of the RNA and its bound proteins on streptavidin-coated resin. After stringent washing, the resin is analyzed by Western blotting or LC-tandem MS (LC-MS/MS) to identify protein interactors. We optimized experimental conditions using the pre(let-7)–Lin28 interaction as proof-of-concept, and our method led to the identification of Lin28 as a specific binding partner for pre(let-7) relative to pre-miR-21 in HEK293T and NTERA-2 cell lines by MS and Western blotting (Fig. S1).

Next, we used our pulldown strategy to identify RBPs for pre-miR-34a. With the aim of uncovering a p53-independent interaction, we opted to conduct experiments in two NSCLC cell lines: A549, which bears WT p53, and H1299, which carries mutant p53. Pre(let-7) was chosen as our negative control such that Lin28 enrichment could serve as an internal control for reproducibility and -fold change enrichment for pre-miR-34a (Fig. 1C). Only two proteins exhibited >2 log₂ -fold change for pre-miR-34a/pre(let-7): SART3 and the DExH-box protein DDX30 (Fig. 1D). Interestingly, the interaction between SART3 and DDX30 has been observed in several cell lines (62), and both proteins have been shown to interact with AGO1 (63). As DDX30 belongs to a highly conserved family of RNA helicases broadly involved in most aspects of RNA biology (64), we turned our focus to SART3, which showed the highest pre-miR-34a enrichment by two methods of label-free relative quantification (Fig. S2). A combined ranking of all proteins highlighted SART3 as a top hit across all cell lines (Fig. 1E), a finding that was also validated by Western blotting (Fig. 1F). Conversely, we also found that miR-34a was enriched upon immunoprecipitation of SART3 (Fig. S3). In further support of our findings, we noted that SART3 had also been detected as a pre-miR-34a-BP via MS-based proteomics in a recent report, which identified this interaction across several cancer cell lines using a test set of 72 pre-miRs (15). From these results, we concluded that SART3 protein interacts with pre-miR-34a with specificity relative to pre(let-7) and several other pre-miRs.

**C-terminal RNA-recognition motifs give rise to selective pre-miR-34a binding**

Having characterized a phenotype related to SART3 expression, we next sought to elucidate a potential mechanism for recognition of pre-miR-34a by SART3. SART3 is a 110-kDa nuclear RBP composed of multiple HAT (half-a-tetratricopeptide repeat) domains, two neighboring nuclear localization sequences (NLSs), and two RNA-recognition motifs (RRMs) (Fig. 2A, top) (65, 66). The HAT domain is a conserved helical motif that has been found in several proteins involved in RNA metabolism (67–69), and the RRM is a domain important for RNA recognition and binding (3, 70). Within SART3 specifically, the HAT domains have roles in pre-mRNA 3’-end processing, ubiquitin-specific protease (USP) recruitment, and
spliceosome recycling (65, 66, 71–74). The NLS allows SART3 to function as a nuclear protein, and the RRMs contribute to RNA recognition, binding, and splicing activity (65, 74).

Recognizing that each of these regions of SART3 could be involved in miRNA regulation, we asked which of these domains were crucial for binding to pre-miR-34a. To this end, we generated 3 × FLAG constructs to express different variants of SART3, each containing deletions or truncations of one or more domains of the protein (Fig. 2B). To assess the binding activity for each construct, we transiently transfected HEK293T cells with each plasmid, subsequently performed pre-miR-34a pulldown experiments as outlined in Fig. 1A, and visualized binding relative to pre-let-7d by Western blotting for the FLAG epitope tag.

We first compared the N and C termini of SART3 with the full-length protein using an empty 3 × FLAG vector as a negative control. Interestingly, we found that the N terminus bound both pre-miR probes, whereas the C terminus was enriched with pre-miR-34a (Fig. 2B). We further investigated the C terminus of SART3 by testing constructs where either of the two RRMs was deleted, as well as a short fragment containing only the RRMs (Fig. 2A). The RRM 1 + 2 fragment appeared to bind pre-miR-34a with the highest specificity relative to pre-let-7d. Moreover, each of the individual RRM deletions showed a moderate enrichment of pre-miR-34a (Fig. 2B). These data suggest that the HAT domains participate in nonspecific RNA binding, whereas the RRMs of SART3 are important for specific binding of pre-miR-34a.

**SART3 knockdown up-regulates miR-34a target genes CDK4 and CDK6**

SART3, also referred to as Tip110, is annotated as a nuclear RBP and has been thoroughly characterized as a spliceosome recycling factor (65, 71, 73–75). SART3 has additional reported roles in pre-mRNA splicing (76), regulation of viral gene transcription (77, 78), histone chaperoning (66, 72), and stem cell growth and pluripotency (65, 79, 80). Moreover, SART3 has been investigated as an antigen for cancer immunotherapies (76, 81–85). Among these reported functions, we found no evidence that SART3 had previously been studied as a modulator of miRNA biogenesis or activity. As such, we first asked whether manipulation of SART3 levels would influence miR-34a expression or that of its target genes. To address this question, we depleted SART3 levels in A549 and H1299 cells via transfection with SART3-targeted siRNA. Robust knockdown of SART3, as well as significant increases in two well-established miR-34a target genes, CDK4 and CDK6 (54, 56), was observed relative to cells transfected with a noncoding siRNA control (Fig. 3A). Cyclin-dependent kinases 4 and 6 (CDK4/6) are cell cycle regulators that facilitate progression through the G1 phase via cyclin D–mediated phosphorylation of the retinoblastoma (RB) protein (86–88). Thus, to explore a functional consequence for up-regulation of CDK4/6, we performed additional knockdown experiments and observed that RB phosphorylation was also increased (Fig. 3A). These initial results suggested that, unlike Lin28-mediated regulation of let-7, SART3 may instead function to facilitate miR-34a maturation.

**SART3 overexpression increases miR-34a levels and decreases CDK4/6**

To test the hypothesis that SART3 promotes miR-34a maturation, we generated stable cell lines overexpressing 1 × FLAG-SART3. Following lentiviral transduction, levels of miR-34a, CDK4, and CDK6 were assessed by quantitative RT-PCR (qRT-PCR). Importantly, we found increased levels of pre-miR-34a, as well as the active and inactive strands of the mature miR-34a duplex (miR-34a and miR-34a*, respectively) upon SART3 overexpression (Fig. 3C). Despite our efforts to quantify or visualize pri-miR-34a by qPCR and Northern blotting, we were unable to detect the primary transcript in any of our cell lines. This was not surprising, as pri-miRNAs are often processed very rapidly or co-transcriptionally. Reciprocal to what was observed after SART3 knockdown, decreased levels of CDK4 and CDK6 were noted at the protein and mRNA levels (Fig. 3B and Fig. S4). Similarly, phosphorylation of RB protein was also decreased concomitantly with CDK4/6 (Fig. 3B). These results indicate that SART3 overexpression leads to increased
miR-34a levels and further support the hypothesis that SART3 has a role in aiding miR-34a biogenesis.

**SART3 overexpression leads to G1 arrest**

Prominent tumor-suppressive functions of miR-34a include induction of cell cycle arrest, senescence, and apoptosis (50–52, 54, 56–58, 89, 90). Due to the well-known roles of CDK4 and CDK6 as cell cycle regulators, our results prompted us to characterize growth and cell cycle distribution in our SART3 overexpressing cell lines. Consistent with the observed decrease in CDK4, CDK6, and phospho-RB upon SART3 overexpression, we found that these cells exhibited dramatic growth inhibition by colony formation assays (Fig. 4A). This slowed growth was in line with what has previously been observed in cancer cells treated with miR-34a, including NSCLC (53, 54, 56, 61, 91).

We next analyzed cell cycle distribution by flow cytometry with propidium iodide–stained cells. In both A549 and H1299 parental lines, substantial growth arrest in the G1 phase was observed upon overexpression of SART3 (Fig. 4B). In addition to cell cycle profiles, we analyzed apoptosis and cellular senescence in these populations. Only a modest increase in apoptosis was detected in SART3-overexpressing cells by annexin V staining (Fig. S6), and no indication of senescence by senescence-associated β-gal staining was found (data not shown).

These experiments provide evidence that high SART3 expression levels induce G1 arrest via the miR-34a-CDK4/6 axis.

**Discussion**

Here we have described a novel miRNA-protein interaction between pre-miR-34a and SART3 in two NSCLC cell lines. Moreover, we have characterized what is, to our knowledge, a new function for the SART3 protein as a modulator of CDK4, CDK6, and cell cycle regulation. Interestingly, the phenotypes we observed indicate that SART3 possesses tumor-suppressive properties in NSCLC cells, which is in contrast to reports describing SART3 as an antigen in other cancers. This would suggest that the functions of SART3 are diverse and not yet fully understood. As such, our results warrant additional studies to...
ACCELERATED COMMUNICATION: Identification of SART3 as a pre-miR-34a–binding protein

probe the SART3 interactome in a more comprehensive fashion.

Although we report compelling evidence of a role for SART3 in the regulation of miR-34a biogenesis, the stage of biogenesis where this interaction occurs remains unclear. It is possible that the second protein identified, DHX30, also plays a role in miR-34a maturation. Notably, both proteins interact with AGO1, but neither has been reported to bind to Drosha, Exportin-5, or Dicer; however, DHX30 interacts with DGC8 (62). Given these networks, it is conceivable that SART3 could act on pri- or pre-miR-34a as part of a larger complex containing DHX30 and Drosha/DGC8. Based on the changes observed in pre- and mature miR-34a levels in response to SART3 overexpression, as well as the annotated roles for SART3 as a nuclear RBP, we hypothesize that this protein acts to facilitate miR-34a processing in the nucleus, likely at the precursor level. However, it is also possible that SART3 interacts with pri-miR-34a, as the precursor hairpin is embedded within the primary transcript (Fig. S7). Either hypothesis is supported by the trends observed in miR-34a target genes in response to altered SART3 expression. Future work will investigate the effects of SART3 on other miRNAs and cellular pathways to better understand the specificity of this RNA-protein interaction.

From a molecular recognition standpoint, our results suggest that the RNA-recognition motifs play an important role in forming a specific interaction with pre-miR-34a. The N terminus of SART3 containing several HAT domains binds RNA in a more promiscuous fashion; thus, we postulate that the RRM contributes toward selectivity and recognition of miR-34a, whereas the N terminus supplies additional RNA-binding capacity. Future work will aim to elucidate a structural basis for this interaction. Such studies will provide added insight into how SART3 functions and will uncover any potential nucleotide sequence or secondary structures important for RNA recognition.

Although significant progress has been made in identifying RBPs as modulators of miRNA biogenesis, our results highlight the need for more detailed functional investigations of these interactions. Characterization of new miR-RBP binding events will improve our current understanding of miRNA regulation in disease, in addition to offering the potential to find new networks for selective therapeutic targeting of dysregulated miRNAs.

**Experimental procedures**

**Cell culture**

A549 (a gift from Dr. Beth Lawlor) and HEK293T cells (a gift from Dr. Carol Fierke) were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. H1299 cells (a gift from Dr. Nouri Neamati) were cultured in RPMI 1640 medium supplemented with 10% FBS and 2 mM L-glutamine. NTERA-2 cells were purchased from ATCC and cultured in Dulbecco’s modified Eagle’s medium with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1% penicillin-streptomycin. Cells were grown at 37 °C with 5% CO2 in a humidified incubator. All cell lines were authenticated by STR profiling and regularly tested for mycoplasma contamination. For knockdown experiments, cells were reverse-transfected in triplicate with 25 nM SART3 SmartPool siRNA (Dharmacon) or siGENOME Nontargeting siRNA 2 (Dharmacon), using 7.5 μl of Lipofectamine RNAiMax (Invitrogen) in 500 μl of Opti-MEM (Gibco) per well of a 6-well dish. Lysates were harvested 48 h after transfection.

**Pre-miR pulldown assays**

Cells were grown to 80% confluence, washed with PBS, and harvested with a cell scraper. Cells were collected in 1 ml of lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 2 mM MgCl2, 10% glycerol, 0.5% Triton X-100, and freshly added protease inhibitor mixture) per 10-cm dish, kept on ice, and lysed by sonication. Lysate concentrations were normalized to 1 mg/ml by BCA assay (Thermo), and 200 μl of lysate was aliquoted for each pulldown. To the lysate aliquots, 100 μl of binding buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 5% glycerol, 0.05% Tween 20, freshly added 2 mM ZnCl2) was added, and a biotinylated pre-miR probe was added to a final concentration of 500 nM. Mixtures were incubated at room temperature for 30 min. To ensure an excess of miRNA relative to beads, 5 μl of streptavidin-coated magnetic resin (Roche Applied Science) per sample was aliquoted and washed with binding buffer. Lysate incubations were added to the streptavidin beads and incubated at room temperature for 1 h with constant agitation. Flow-throughs from each pulldown were collected, and resins were washed once with a stringent buffer (100 mM phosphate, pH 7, 200 mM NaCl, 0.25% Tween 20) and three times with PBS.

![Figure 4. Increased SART3 expression results in growth inhibition and cell cycle arrest in G1 phase.](image-url)

**Table 1.** Average % total population in phase

<table>
<thead>
<tr>
<th>Treatment</th>
<th>G1</th>
<th>S</th>
<th>G2</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549 Sham</td>
<td>56.5 ± 1.5%</td>
<td>29.8 ± 1.2%</td>
<td>13.0 ± 1.0%</td>
</tr>
<tr>
<td>A549 SART3 OE</td>
<td>64.0 ± 2.6%</td>
<td>20.1 ± 1.6%</td>
<td>16.8 ± 4.5%</td>
</tr>
<tr>
<td>H1299 Sham</td>
<td>33.3 ± 1.4%</td>
<td>48.3 ± 1.1%</td>
<td>18.2 ± 2.3%</td>
</tr>
<tr>
<td>H1299 SART3 OE</td>
<td>39.8 ± 1.0%</td>
<td>39.6 ± 0.8%</td>
<td>20.1 ± 2.6%</td>
</tr>
</tbody>
</table>
Protein identification by LC-MS/MS

Protocols for in-solution digestion are adapted from Yu et al. (92). Beads were resuspended in 50 μl of 0.1 M NH₄HCO₃ buffer (pH ~8). Cysteines were reduced by adding 50 μl of 10 mM DTT and incubating at 45 °C for 30 min. Samples were cooled to room temperature, and cysteines were alkylated with 65 mM 2-chloroacetaldehyde for 30 min at room temperature. Proteins were digested overnight with 1 μg of sequencing grade trypsin at 37 °C. Digestion was stopped by acidification, and peptides were desalted using SepPak C18 cartridges (Waters) and then dried using a Vacufuge concentrator (Eppendorf). Resulting peptides were dissolved in 8 μl of 0.1% formic acid, 2% acetonitrile solution, and 2 μl of peptide solution was resolved on a nanocapillary reverse-phase column (Acclaim PepMap C18, 2 μm, 50 cm, Thermo) over 180 min. Eluent was directly introduced into an Orbitrap Fusion mass spectrometer (Thermo) using an EasySpray source. MS1 scans were acquired at 120,000 resolution (AGC target = 1 × 10⁶; maximum IT = 50 ms). Data-dependent collision-induced dissociation MS/MS spectra were acquired using the top speed method (3 s) following each MS1 scan (normalized collision energy ~32%; AGC target 1 × 10⁶; maximum IT = 45 ms). Protein identification and quantification was performed using MaxQuant (version 1.6.7.0) (93). MS/MS spectra were searched with Andromeda against the reference human database from Uniprot (February 2, 2014 download, 39,882 sequences) appended with common contaminants and the automatically generated reverse database for the reference human database. All replicates are biological. The MS proteomics data is also shown in Table S1.

Lentivirus production and infection

1×FLAG-SART3 was amplified from A549 cDNA and cloned into pLentilox-IRE-S-Puro (obtained from University of Michigan vector core) by standard PCR with NheI and XhoI restriction enzymes (see Table S2 for primers). Lentiviruses were packaged, and stable cell lines were generated as described (95).

Western blotting

All lysates were prepared, and immunoblotting was performed as described previously (95). The antibodies used in this work are listed in Table S2.

RNA isolation and qRT-PCR

Total and small RNA were isolated using the mirVana miRNA isolation kit (Invitrogen). For mRNA quantification, cDNA was prepared from total RNA using the Superscript III first-strand synthesis kit (Invitrogen) according to the manufacturer’s instructions. PowerUP SYBR Green master mix (Applied Biosystems) was used for gene expression analysis. For miRNA quantification, cDNA was prepared from small RNA using the miScript II RT kit (Qiagen) using the manufacturer’s instructions. miScript SYBR Green PCR kit (Qiagen) was used for miRNA expression analysis. All qPCR was performed on a ViiA7 thermocycler using the fast qPCR protocol, and relative -fold change was calculated using the comparative threshold (Cₜ) method. Primers used in this work are listed in Table S2.

Cell cycle analysis was performed as described (94). For apoptosis analysis, cells were grown to 70% confluence, collected 96 h post-transduction, and stained with annexin V–Alexa Fluor(TM) 488 (Invitrogen) according to the manufacturer’s protocol. Fluorescence of stained cellular DNA content and/or annexin V conjugates were measured on a CytoFLEX Flow Cytometer (Beckman-Coulter). Cells were gated and analyzed using FlowJo software (version 10).

3×FLAG-SART3 variant cloning

Full-length SART3 and all variants were amplified from our pLentilox-1×FLAG-SART3 vector using standard PCR and cloned into pcDNA3 containing a 3×FLAG tag (95) using EcoRI and Xbal restriction enzymes. All primers used for cloning are listed in Table S2.

Acknowledgments—We thank Dr. Venkatesha Basrur and Kevin Conlon (University of Michigan Proteomics Resource Facility) for assistance in generating proteomics data. We thank Prof. Johnny He’s laboratory at the University of North Texas Health Science Center for gifting us with a SART3 antibody that was used in some preliminary experiments. Finally, we thank Dr. Dan Lorenz for intellectual contributions to this work and Dr. Pat O’Brien for input on the manuscript.

References
Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41, 843–848 CrossRef Medline


ACCELERATED COMMUNICATION: Identification of SART3 as a pre-miR-34a–binding protein


